The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis
Phase 2
Completed
- Conditions
- InfertilityAutoimmune Thyroiditis
- Interventions
- Drug: ImmunomodulatoryDrug: Thyroxine
- Registration Number
- NCT03289403
- Lead Sponsor
- Aljazeera Hospital
- Brief Summary
The aim of the work is to determine whether the use of immunomodulatory drugs could improve the reproductive of outcome of infertile patients who have autoimmune thyroiditis with positive autoimmune antibodies undergoing IVF-ET.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 194
Inclusion Criteria
- Infertility patients who have autoimmune thyroiditis With positive autoimmune thyroiditis and TSH level above 2 IU.
Read More
Exclusion Criteria
- All patients who have other autoimmune diseases especially antiphospholipid syndrome, hepatitis c viral disease.
Patients who have any medical disorders ( eg. D.M. HTN .Epilepsy ....)
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Study group Immunomodulatory Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D and immunomodulatory drugs(prednisolone, hydroxychloroquine, azathioprin, IV immunoglobulins) Control group Thyroxine Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D.
- Primary Outcome Measures
Name Time Method The Number of Participants Who Achieved clinical Pregnancy 6 weeks after embryo transfer
- Secondary Outcome Measures
Name Time Method The Number of Participants Who Achieved Ongoing Pregnancy 18 weeks after embryo transfer
Trial Locations
- Locations (1)
Aljazeera (Al Gazeera) hospital
🇪🇬Giza, Egypt